for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

BNTX.O

Latest Trade

121.59USD

Change

11.60(+10.55%)

Volume

8,786,293

Today's Range

113.50

 - 

124.91

52 Week Range

20.72

 - 

124.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
109.99
Open
113.64
Volume
8,786,293
3M AVG Volume
66.31
Today's High
124.91
Today's Low
113.50
52 Week High
124.91
52 Week Low
20.72
Shares Out (MIL)
232.67
Market Cap (MIL)
26,592.98
Forward P/E
-83.01
Dividend (Yield %)
--

Latest Developments

More

BioNTech And InstaDeep Announce Strategic Collaboration

Biontech And Fosun Pharma Announce Start Of Phase 2 Clinical Trial Of Lead mRNA Covid-19 Vaccine BNT162B2 In China

Pfizer And Biontech To Submit Emergency Use Authorization Request Today To U.S. FDA For COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.4K
EPS (EUR)

2019

-0.850

2020(E)

-0.850
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
23.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
33.50
LT Debt To Equity (MRQ)
18.93
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Russia says its Sputnik V COVID-19 vaccine is 92% effective

Russia's Sputnik V vaccine is 92% effective at protecting people from COVID-19 according to interim trial results, the country's sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

Q&A: Where are we in the COVID-19 vaccine race?

Drugmakers and research centers around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway.

Coronavirus vaccine hope dampens prospects for corporate stay-at-home darlings

The surge in shares of Netflix <NFLX.O>, Zoom <ZM.O> and other of this year's stay-at-home corporate winners has been brought to a sudden halt by promising vaccine data suggesting a possible way out of the COVID-19 pandemic.

U.S. has a plan to start Pfizer vaccine shots in December: Health Secretary Azar

If Pfizer Inc <PFE.N> submits the positive initial data from its COVID-19 vaccine trial to health regulators as quickly as expected, the U.S. government plans to begin vaccinating Americans in December, Health Secretary Alex Azar said on Tuesday.

Spain hopes to receive first Pfizer vaccines in early 2021 - minister

Spain stands to receive its first vaccines against COVID-19 developed by Pfizer <PFE.N> and its partner BioNTech <22UAy.DE> in early 2021, the health minister said on Tuesday, under a deal being negotiated by the European Union.

European stocks hold eight-month highs despite lockdown fears

European shares held near eight-month highs on Tuesday, riding a wave of optimism about a COVID-19 vaccine breakthrough, although concerns about the pandemic's economic damage capped gains.

Expert Views: Pfizer, BioNTech say their COVID-19 vaccine is more than 90% effective

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

Factbox: Development of Pfizer-BioNTech coronavirus vaccine

U.S. drugmaker Pfizer and German partner BioNTech on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.

Brazil in talks with Pfizer to buy promising COVID-19 vaccine

The Brazilian federal government is in talks with Pfizer Inc <PFE.N> in Brazil to buy its experimental COVID-19 vaccine for inclusion in its national vaccination program, a spokesman for the company said on Monday.

COVID-19 vaccine could help fundamentally change pandemic's arc: WHO

A COVID-19 vaccine may be rolled out by March 2021 to the most vulnerable, which along with other advances could fundamentally change the course of the pandemic, a senior World Health Organization (WHO) official said on Monday.

Factbox: The race for a coronavirus vaccine

Pfizer <PFE.N> and German partner BioNTech <22UAy.F> on Monday became the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine, priming it for possible speedy regulatory approvals.

Vaccine news catapults investors' economic-recovery bets

News of an effective vaccine against the novel coronavirus is fueling bets that a global economic recovery will buoy wide swaths of the market that have struggled under nearly nine months of the COVID-19 pandemic.

We may soon have a COVID-19 vaccine. But will enough people take it?

With COVID-19 vaccine trial results looking positive, governments and pharmaceutical firms face their next daunting challenge: convincing the world to get inoculated.

Energy, travel stocks surge on Pfizer vaccine hopes

Shares of stocks that have been demolished as the coronavirus and related lockdowns have crippled the global economy surged on Monday following positive news from Pfizer <PFE.N> and its German partner BioNTech <22UAy.DE> about is experimental COVID-19 vaccine.

Germany encouraged by Pfizer COVID-19 vaccine news, cautious on timeline

Germany's health minister is encouraged by a Pfizer <PFE.N> announcement that its COVID-19 vaccine proved effective in a late-stage trial but still does not expect a shot to be available before the first quarter of 2021, he said on Monday.

BioNTech hopes COVID-19 vaccine will immunize for at least a year

BioNTech's <BNTX.O> co-founder and chief executive said he was optimistic that the protective effect of its experimental COVID-19 vaccine, co-developed with Pfizer <PFE.N>, would last for at least a year.

Biden welcomes Pfizer coronavirus vaccine news, says safety measures still needed

U.S. president-elect Joe Biden greeted Pfizer Inc's experimental COVID-19 vaccine as excellent news on Monday, but warned that widespread vaccination remains months away and Americans need to continue wearing masks and maintain social distancing.

India sees early vaccine launch as AstraZeneca deliveries run late

India raced ahead with work on its coronavirus vaccine while Britain's AstraZeneca said its deliveries were running "a little bit late" as countries around the world sought to conquer the pandemic and rescue their economies.

Exclusive: India-made COVID-19 vaccine could be launched as early as February - government scientist

An Indian government-backed COVID-19 vaccine could be launched as early as February - months earlier than expected - as last-stage trials begin this month and studies have so far showed it is safe and effective, a senior government scientist told Reuters.

Australia orders more COVID-19 vaccines for total of 135 million doses

The Australian government has agreed to purchase two more COVID-19 vaccines in development, beefing up the country's prospective arsenal against the pandemic to 135 million doses as it aims to complete a mass inoculation programme within months.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up